Premium
Pharmacologic Effects of A‐56234, a New High‐Ceiling Diuretic
Author(s) -
Luther Robert R.,
Ringham Gary L.,
Thomas Elizabeth W.,
Patterson Karen J.,
Tolman Keith G.
Publication year - 1988
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1988.tb03218.x
Subject(s) - diuretic , pharmacokinetics , urine , pharmacology , medicine , excretion , drug , placebo , oral administration , alternative medicine , pathology
The pharmacokinetic characteristics, the diuretic, saluretic, and uricosuric properties, and the safety of single, rising, oral doses of A‐56234, a new high‐ceiling diuretic, were evaluated in this double‐blind, placebo‐controlled, cross‐over study. Each of three groups of eight subjects received placebo and three different single doses of the diuretic at 1‐week intervals. Doses ranged from 0.5 to 80 mg. Significant, dose‐related increases in urine volume and in urinary excretion of sodium and chloride were produced during the 24 hours after administration of 20, 40, 60, and 80 mg of the drug. Uricosuria was not observed at any dose. The drug was rapidly absorbed and displayed linear pharmacokinetics within the dose range studied. The elimination‐phase plasma half‐life was approximately 6 hours. Hepatic clearance was the main route of excretion in humans; only 2 to 10% of the parent drug was excreted in the urine. The drug was well tolerated and no clinically important adverse events were noted.